NYSEAMERICAN:TRXC

TransEnterix Stock Forecast, Price & News

$3.22
-0.02 (-0.62 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.13
$3.40
50-Day Range
$0.36
$1.17
52-Week Range
$0.28
$6.95
Volume8.70 million shs
Average Volume44.56 million shs
Market Capitalization$459.74 million
P/E RatioN/A
Dividend YieldN/A
Beta2.56
30 days | 90 days | 365 days | Advanced Chart
Receive TRXC News and Ratings via Email

Sign-up to receive the latest news and ratings for TransEnterix and its competitors with MarketBeat's FREE daily newsletter.


TransEnterix logo

About TransEnterix

TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.59 out of 5 stars

Medical Sector

1440th out of 2,096 stocks

Surgical & Medical Instruments Industry

131st out of 174 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions

Is TransEnterix a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TransEnterix stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRXC, but not buy additional shares or sell existing shares.
View analyst ratings for TransEnterix
or view top-rated stocks.

What stocks does MarketBeat like better than TransEnterix?

Wall Street analysts have given TransEnterix a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TransEnterix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were TransEnterix's earnings last quarter?

TransEnterix, Inc. (NYSEAMERICAN:TRXC) released its quarterly earnings data on Thursday, November, 5th. The medical instruments supplier reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.11. The medical instruments supplier had revenue of $0.81 million for the quarter, compared to analyst estimates of $0.73 million. TransEnterix had a negative net margin of 2,149.15% and a negative trailing twelve-month return on equity of 83.74%.
View TransEnterix's earnings history
.

Who are TransEnterix's key executives?

TransEnterix's management team includes the following people:
  • Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
  • Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
  • Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
  • Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
  • Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)

Who are some of TransEnterix's key competitors?

What other stocks do shareholders of TransEnterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), Actinium Pharmaceuticals (ATNM), XOMA (XOMA), Geron (GERN), OPKO Health (OPK), NVIDIA (NVDA) and Advanced Micro Devices (AMD).

What is TransEnterix's stock symbol?

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

How do I buy shares of TransEnterix?

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransEnterix's stock price today?

One share of TRXC stock can currently be purchased for approximately $3.22.

How much money does TransEnterix make?

TransEnterix has a market capitalization of $459.74 million and generates $8.53 million in revenue each year. The medical instruments supplier earns $-154,200,000.00 in net income (profit) each year or ($4.22) on an earnings per share basis.

What is TransEnterix's official website?

The official website for TransEnterix is www.transenterix.com.

Where are TransEnterix's headquarters?

TransEnterix is headquartered at 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States.

How can I contact TransEnterix?

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400 or via email at [email protected]


This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.